Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTRA-CKD Trial
NCT07524101Recruiting
- Sponsor
- Yonsei University
- Start
- May 2026
- Primary completion
- Jan 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Yonsei University. Primary endpoint: Major Adverse Cardiovascular Events at 3 years. Started May 2026; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07524101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524101.